Control BionicsASX:CBL +4.29% Receivables Turnover is 2.11 as of Dec. 2025. The stock has 4 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Control Bionics ranks worse than 72.13% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Control Bionics's Revenue for the
six
months ended in Dec. 2025 was A$2.76 Mil. Control Bionics's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$1.31 Mil.
Hence, Control Bionics's Receivables Turnover for the
six
months ended in Dec. 2025 was 2.11.
Control Bionics (ASX:CBL) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Control Bionics Receivables Turnover Related Terms
Control Bionics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Control Bionics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Control Bionics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Control Bionics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Receivables Turnover of 2.11 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #585 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 72.1%.
Is Control Bionics' Receivables Turnover too high?
Control Bionics' current Receivables Turnover is 2.11. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Control Bionics' value of 2.11 is 61.7% below this industry median. Based on the distribution chart, Control Bionics ranks #585 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Control Bionics' Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #585 out of 811 companies for Receivables Turnover. This places Control Bionics in the lower half of its industry. The industry median Receivables Turnover is 5.51. Control Bionics' value of 2.11 is 61.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Receivables Turnover of 2.11 is 61.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Receivables Turnover is 2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 143.3% above its estimated fair value. The current Receivables Turnover is 2.11 and 61.7% below the Medical Devices & Instruments industry median of 5.51. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Receivables Turnover is 2.11 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 